Adam Horvit, MD
Neurology · Round Rock, TXNPI 1578590105
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $63,845 of the $74,498 with a category attached, or 85.7%. 40 manufacturers reported payments, led by AstraZeneca at 56.0% of the total. Among neurology clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 268 payments — averaging $277.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$42K
- Argenx US, Inc.$29K
- Genentech USA, Inc.$408
- Octapharma USA, Inc.$374
- AbbVie$290
- EDW Pharma, Inc.$288
- plus $2K from 34 others
Across 30 payments — averaging $7848.35 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$208K
- Novartis$12K
- Genentech, Inc.$8K
- Takeda Pharmaceuticals U.S.A., Inc.$8K
What the payments were for
- Speaking & faculty fees$63,84586%
- Travel & lodging$4,2576%
- Food & beverage$6,3689%
- Education$280%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 58 | $41,686 |
| Argenx US, Inc. | 33 | $29,123 |
| Genentech USA, Inc. | 32 | $408 |
| Octapharma USA, Inc. | 12 | $374 |
| AbbVie(2 entities) | 15 | $290 |
| EDW Pharma, Inc. | 1 | $288 |
| Acadia Pharmaceuticals Inc | 17 | $271 |
| Biogen | 7 | $211 |
| Teva Pharmaceuticals USA, Inc. | 11 | $181 |
| Pfizer | 20 | $177 |
| Genentech, Inc. | 1 | $141 |
| Tanabe Pharma America, Inc. | 7 | $140 |
| Akcea Therapeutics, Inc. | 2 | $133 |
| UCB, Inc. | 3 | $101 |
| Sanofi | 4 | $85 |
| Amgen | 4 | $82 |
| EMD Serono, Inc. | 6 | $78 |
| Novartis | 4 | $74 |
| SK Life Science, Inc. | 3 | $63 |
| Grifols USA, LLC | 3 | $60 |
| Averitas Pharma Inc. | 2 | $50 |
| Lilly USA, LLC | 3 | $50 |
| Lundbeck LLC | 1 | $48 |
| Abbott | 2 | $37 |
| Microtransponder, Inc. | 1 | $35 |
| Amylyx Pharmaceuticals, Inc. | 1 | $32 |
| MDD US Operations, LLC | 2 | $31 |
| Alnylam Pharmaceuticals Inc. | 1 | $27 |
| Eisai Inc. | 1 | $24 |
| Catalyst Pharmaceuticals, Inc. | 1 | $23 |
| ANI Pharmaceuticals, Inc. | 1 | $22 |
| Greenwich Biosciences, Inc. | 1 | $21 |
| Neurocrine Biosciences, Inc. | 1 | $20 |
| Amicus Therapeutics, Inc. | 1 | $20 |
| Johnson & Johnson | 1 | $19 |
| Jazz Pharmaceuticals Inc. | 1 | $18 |
| Life Molecular Imaging Ltd | 1 | $17 |
| Novo Nordisk | 1 | $15 |
| Shire North American Group Inc | 1 | $15 |
| Avanir Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ULTOMIRIS$34,830
- VYVGART HYTRULO$15,912
- VYVGART$11,577
- SOLIRIS$930
- Tiglutik$288
- EVRYSDI$141
- TEGSEDI$114
- OCTAGAM IMMUNE GLOBULIN (HUMAN)$107
- SPINRAZA$102
How this compares
$74,498 in reported general payments places this provider in the 90th percentile of 1,246 neurology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Radicava OrsEdaravone | 19 | $266,765 |
| Gabapentin | 466 | $9,538 |
| Rivastigmine | 45 | $6,854 |
| Tramadol Hcl ErTramadol Hcl | 25 | $4,064 |
| Pyridostigmine Bromide | 87 | $3,971 |
| Pregabalin | 178 | $3,922 |
| Duloxetine Hcl | 192 | $3,823 |
| Mycophenolate Mofetil | 43 | $3,021 |
| Donepezil Hcl | 194 | $2,019 |
| Levetiracetam | 67 | $1,671 |
| Memantine Hcl | 121 | $1,615 |
| Ropinirole Hcl | 37 | $1,080 |
| Oxcarbazepine | 15 | $1,032 |
| Memantine Hcl ErMemantine Hcl | 15 | $985 |
| Prednisone | 106 | $707 |
Paid to pharmacies, not to this prescriber.
Other neurology in Round Rock
- Ann BassSan Antonio$1.7M
- William OndoHouston$1.4M
- Nirav PavasiaDallas$1.4M
- Mirla AvilaLubbock$1.3M
- Michael SoileauGeorgetown$1.2M
- Pankaj SatijaHouston$1.1M
- Annette HowardHouston$826K
- Benjamin GreenbergDallas$773K
- Annette OkaiPlano$730K
- Waleed El-FekyDallas$587K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.